Aptamer Group shares jump on new Unilever collab

Aptamer Group PLC (AIM:APTA) shares rose 11.6% to 0.38p after announcing a second Optimer development agreement with Unilever, expanding their partnership beyond the initial body odour enzyme inhibition project. The new project targets a separate biological pathway, with Aptamer receiving a six-figure fee for services. CEO Dr. Arron Tolley noted the deal reflects Unilever's confidence in Optimer technology, with the first project now advancing to on-person trials, potentially leading to multiple licensable assets.

Analysis

Aptamer Group PLC has solidified its relationship with Unilever by securing a second Optimer development agreement, subsequent to a successful initial program targeting enzymes linked to body odour, which is now progressing to on-person trials. This new project, which focuses on a different biological pathway, will see Aptamer develop new binders in exchange for a 'six-figure' service fee. This development not only signifies Unilever's growing confidence in Aptamer's Optimer platform but also expands its application into the consumer health market. Chief Executive Dr Arron Tolley highlighted the potential to create multiple, licensable assets with a global consumer goods company. The market reacted favorably to this news, with Aptamer's shares climbing 11.6% to 0.38p, indicating positive investor sentiment regarding the enhanced commercial prospects and validation of its technology.

Key Decisions for Investors

• Investors should view the expanded Unilever partnership as a material validation of Aptamer's Optimer platform and a positive indicator of its potential to generate future licensing revenue from the consumer health market.
• Closely monitor upcoming milestones, particularly the results from the on-person trials of the first Unilever project and progress reports on this new development, as these will be key de-risking events and potential catalysts for Aptamer's valuation.
• While this specific agreement is of a modest financial scale for Unilever, it underscores their ongoing strategy of leveraging external R&D for innovation, which may present further opportunities for specialized technology providers like Aptamer.